Search Results - "Dubois, Bruno"

Apathy and the Functional Anatomy of the Prefrontal Cortex–Basal Ganglia Circuits by Levy, Richard, Dubois, Bruno

“…The clinical signs grouped under the concept of apathy are a common feature of prefrontal and basal ganglia lesions or dysfunctions and can therefore help to…”
Get full text

Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges by Dubois, Bruno, Padovani, Alessandro, Scheltens, Philip, Rossi, Andrea, Dell'Agnello, Grazia

“…Timely diagnosis of Alzheimer's disease (AD) refers to a diagnosis at the stage when patients come to the attention of clinicians because of concerns about…”
Get more information

The probabilistic model of Alzheimer disease: the amyloid hypothesis revised by Frisoni, Giovanni B., Altomare, Daniele, Thal, Dietmar Rudolf, Ribaldi, Federica, van der Kant, Rik, Ossenkoppele, Rik, Blennow, Kaj, Cummings, Jeffrey, van Duijn, Cornelia, Nilsson, Peter M., Dietrich, Pierre-Yves, Scheltens, Philip, Dubois, Bruno

“…The current conceptualization of Alzheimer disease (AD) is driven by the amyloid hypothesis, in which a deterministic chain of events leads from amyloid…”
Get full text

MDS research criteria for prodromal Parkinson's disease by Berg, Daniela, Postuma, Ronald B., Adler, Charles H., Bloem, Bastiaan R., Chan, Piu, Dubois, Bruno, Gasser, Thomas, Goetz, Christopher G., Halliday, Glenda, Joseph, Lawrence, Lang, Anthony E., Liepelt-Scarfone, Inga, Litvan, Irene, Marek, Kenneth, Obeso, José, Oertel, Wolfgang, Olanow, C. Warren, Poewe, Werner, Stern, Matthew, Deuschl, Günther

“…ABSTRACT This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein…”
Get full text

A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease by Ostrowitzki, Susanne, Lasser, Robert A, Dorflinger, Ernest, Scheltens, Philip, Barkhof, Frederik, Nikolcheva, Tania, Ashford, Elizabeth, Retout, Sylvie, Hofmann, Carsten, Delmar, Paul, Klein, Gregory, Andjelkovic, Mirjana, Dubois, Bruno, Boada, Mercè, Blennow, Kaj, Santarelli, Luca, Fontoura, Paulo

“…Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the…”
Get full text

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease by Blennow, Kaj, Dubois, Bruno, Fagan, Anne M, Lewczuk, Piotr, de Leon, Mony J, Hampel, Harald

“…Abstract Several potential disease-modifying drugs for Alzheimer's disease (AD) have failed to show any effect on disease progression in clinical trials,…”
Get full text

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria by Dubois, Bruno, Prof, Feldman, Howard H, Prof, Jacova, Claudia, PhD, Hampel, Harald, Prof, Molinuevo, José Luis, MD, Blennow, Kaj, MD, DeKosky, Steven T, Prof, Gauthier, Serge, Prof, Selkoe, Dennis, Prof, Bateman, Randall, MD, Cappa, Stefano, MD, Crutch, Sebastian, PhD, Engelborghs, Sebastiaan, MD, Frisoni, Giovanni B, Prof, Fox, Nick C, MD, Galasko, Douglas, Prof, Habert, Marie-Odile, MD, Jicha, Gregory A, MD, Nordberg, Agneta, MD, Pasquier, Florence, Prof, Rabinovici, Gil, MD, Robert, Philippe, Prof, Rowe, Christopher, MD, Salloway, Stephen, Prof, Sarazin, Marie, Prof, Epelbaum, Stéphane, MD, de Souza, Leonardo C, MD, Vellas, Bruno, Prof, Visser, Pieter J, MD, Schneider, Lon, Prof, Stern, Yaakov, Prof, Scheltens, Philip, Prof, Cummings, Jeffrey L, Prof

“…Summary In the past 8 years, both the International Working Group (IWG) and the US National Institute on Aging–Alzheimer's Association have contributed…”
Get full text

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria by Dubois, Bruno, MD, Feldman, Howard H, MD, Jacova, Claudia, PhD, DeKosky, Steven T, MD, Barberger-Gateau, Pascale, MD, Cummings, Jeffrey, MD, Delacourte, André, PhD, Galasko, Douglas, MD, Gauthier, Serge, MD, Jicha, Gregory, MD, Meguro, Kenichi, MD, O'Brien, John, MD, Pasquier, Florence, MD, Robert, Philippe, MD, Rossor, Martin, MD, Salloway, Steven, MD, Stern, Yaakov, PhD, Visser, Pieter J, MD, Scheltens, Philip, MD

“…Summary The NINCDS–ADRDA and the DSM-IV-TR criteria for Alzheimer's disease (AD) are the prevailing diagnostic standards in research; however, they have now…”
Get full text

Implementation of subjective cognitive decline criteria in research studies by Molinuevo, José L, Rabin, Laura A, Amariglio, Rebecca, Buckley, Rachel, Dubois, Bruno, Ellis, Kathryn A, Ewers, Michael, Hampel, Harald, Klöppel, Stefan, Rami, Lorena, Reisberg, Barry, Saykin, Andrew J, Sikkes, Sietske, Smart, Colette M, Snitz, Beth E, Sperling, Reisa, van der Flier, Wiesje M, Wagner, Michael, Jessen, Frank

“…Abstract Introduction Subjective cognitive decline (SCD) manifesting before clinical impairment could serve as a target population for early intervention…”
Get full text

EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease by Gaubert, Sinead, Raimondo, Federico, Houot, Marion, Corsi, Marie-Constance, Naccache, Lionel, Diego Sitt, Jacobo, Hermann, Bertrand, Oudiette, Delphine, Gagliardi, Geoffroy, Habert, Marie-Odile, Dubois, Bruno, De Vico Fallani, Fabrizio, Bakardjian, Hovagim, Epelbaum, Stéphane

“…Early biomarkers are needed to identify individuals at high risk of preclinical Alzheimer's disease and to better understand the pathophysiological processes…”
Get full text

A phase II trial of tideglusib in Alzheimer's disease by Lovestone, Simon, Boada, Mercè, Dubois, Bruno, Hüll, Michael, Rinne, Juha O, Huppertz, Hans-Jürgen, Calero, Miguel, Andrés, María V, Gómez-Carrillo, Belén, León, Teresa, del Ser, Teodoro

“…The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer's disease (AD). To prove the clinical…”
Get more information

Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease by Berg, Daniela, Postuma, Ronald B., Bloem, Bastiaan, Chan, Piu, Dubois, Bruno, Gasser, Thomas, Goetz, Christopher G., Halliday, Glenda M., Hardy, John, Lang, Anthony E., Litvan, Irene, Marek, Kenneth, Obeso, José, Oertel, Wolfgang, Olanow, C. Warren, Poewe, Werner, Stern, Matthew, Deuschl, Günther

“…ABSTRACT With advances in knowledge disease, boundaries may change. Occasionally, these changes are of such a magnitude that they require redefinition of the…”
Get full text

Drug development in Alzheimer's disease: the path to 2025 by Cummings, Jeffrey, Aisen, Paul S, DuBois, Bruno, Frölich, Lutz, Jack, Jr, Clifford R, Jones, Roy W, Morris, John C, Raskin, Joel, Dowsett, Sherie A, Scheltens, Philip

“…The global impact of Alzheimer's disease (AD) continues to increase, and focused efforts are needed to address this immense public health challenge. National…”
Get full text

On the path to 2025: understanding the Alzheimer's disease continuum by Aisen, Paul S, Cummings, Jeffrey, Jack, Jr, Clifford R, Morris, John C, Sperling, Reisa, Frölich, Lutz, Jones, Roy W, Dowsett, Sherie A, Matthews, Brandy R, Raskin, Joel, Scheltens, Philip, Dubois, Bruno

“…Basic research advances in recent years have furthered our understanding of the natural history of Alzheimer's disease (AD). It is now recognized that…”
Get full text

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease by Albert, Marilyn S, DeKosky, Steven T, Dickson, Dennis, Dubois, Bruno, Feldman, Howard H, Fox, Nick C, Gamst, Anthony, Holtzman, David M, Jagust, William J, Petersen, Ronald C, Snyder, Peter J, Carrillo, Maria C, Thies, Bill, Phelps, Creighton H

“…Abstract The National Institute on Aging and the Alzheimer’s Association charged a workgroup with the task of developing criteria for the symptomatic…”
Get full text

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy by Millan, Mark J., Agid, Yves, Brüne, Martin, Bullmore, Edward T., Carter, Cameron S., Clayton, Nicola S., Connor, Richard, Davis, Sabrina, Deakin, Bill, DeRubeis, Robert J., Dubois, Bruno, Geyer, Mark A., Goodwin, Guy M., Gorwood, Philip, Jay, Thérèse M., Joëls, Marian, Mansuy, Isabelle M., Meyer-Lindenberg, Andreas, Murphy, Declan, Rolls, Edmund, Saletu, Bernd, Spedding, Michael, Sweeney, John, Whittington, Miles, Young, Larry J.

“…Key Points Deficits in cognitive function — ranging from decreased attention and working memory to disrupted social cognition and language — are common in…”
Get full text

Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants by Dubois, Bruno, von Arnim, Christine A F, Burnie, Nerida, Bozeat, Sasha, Cummings, Jeffrey

“…Development of in vivo biomarkers has shifted the diagnosis of Alzheimer's disease (AD) from the later dementia stages of disease towards the earlier stages…”
Get full text

Revising the definition of Alzheimer's disease: a new lexicon by Dubois, Bruno, Prof, Feldman, Howard H, Prof, Jacova, Claudia, PhD, Cummings, Jeffrey L, MD, DeKosky, Steven T, Prof, Barberger-Gateau, Pascale, MD, Delacourte, André, PhD, Frisoni, Giovanni, Prof, Fox, Nick C, Prof, Galasko, Douglas, Prof, Gauthier, Serge, Prof, Hampel, Harald, Prof, Jicha, Gregory A, MD, Meguro, Kenichi, MD, O'Brien, John, DM, Pasquier, Florence, Prof, Robert, Philippe, Prof, Rossor, Martin, Prof, Salloway, Steven, Prof, Sarazin, Marie, MD, de Souza, Leonardo C, MD, Stern, Yaakov, Prof, Visser, Pieter J, MD, Scheltens, Philip, Prof

“…Summary Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that…”
Get full text

Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging by Gerardin, Emilie, Chételat, Gaël, Chupin, Marie, Cuingnet, Rémi, Desgranges, Béatrice, Kim, Ho-Sung, Niethammer, Marc, Dubois, Bruno, Lehéricy, Stéphane, Garnero, Line, Eustache, Francis, Colliot, Olivier

“…We describe a new method to automatically discriminate between patients with Alzheimer's disease (AD) or mild cognitive impairment (MCI) and elderly controls,…”
Get full text

The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative by Molinuevo, José Luis, Blennow, Kaj, Dubois, Bruno, Engelborghs, Sebastiaan, Lewczuk, Piotr, Perret-Liaudet, Armand, Teunissen, Charlotte E, Parnetti, Lucilla

“…Abstract Background Cerebrospinal fluid (CSF) biomarkers β-amyloid 1-42 (Aβ1-42 ), also expressed as Aβ1-42 :Aβ1-40 ratio, T-tau, and P-tau181P , have proven…”
Get full text